Secnidazole Patent Expiration
Secnidazole is Used for treating bacterial vaginosis and trichomoniasis in women and female patients 12 years of age and older. It was first introduced by Evofem Inc
Secnidazole Patents
Given below is the list of patents protecting Secnidazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Solosec | US11684607 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 16, 2035 | Evofem Inc |
| Solosec | US10335390 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US10682338 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US10849884 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US10857133 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US11000507 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US11000508 | Secnidazole for use in the treatment of trichomoniasis | Sep 04, 2035 | Evofem Inc |
| Solosec | US11020377 | Secnidazole for use in the treatment of bacterial vaginosis | Sep 04, 2035 | Evofem Inc |
| Solosec | US11324721 | Secnidazole for use in the treatment of trichomoniasis | Sep 04, 2035 | Evofem Inc |
| Solosec | US11602522 | Secnidazole for use in the treatment of sexually transmitted infection | Sep 04, 2035 | Evofem Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Secnidazole's patents.
Latest Legal Activities on Secnidazole's Patents
Given below is the list recent legal activities going on the following patents of Secnidazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000507 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000508 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10849884 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10857133 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jun, 2023 | US10682338 |
| Electronic Review Critical | 27 Jun, 2023 | US11684607 |
| Email Notification Critical | 27 Jun, 2023 | US11684607 |
| Mail Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
| Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
| Patent Issue Date Used in PTA Calculation Critical | 27 Jun, 2023 | US11684607 |
Secnidazole's Family Patents
